Latanoprostene Bunod
Brand Names: Vyzulta
Methodology & AI Transparency ⓘ
Latanoprostene Bunod Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage vyzulta: ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- 2 Real-world patient consensus: Real-world cohort score of 78% across 20 de-identified Latanoprostene Bunod entries.
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($99.2842/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Latanoprostene Bunod tolerability events: peripheral edema (4%), application-site irritation (4%), nausea (7.6%).
Ask our AI Specialists anything about Latanoprostene Bunod
Latanoprostene Bunod Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage vyzulta: ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. VYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )
12.1 Mechanism of Action Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.
Systemic exposure to Latanoprostene Bunod reflects Oral fraction absorbed ranges from 56% to 68% (Latanoprostene Bunod .24) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of latanoprostene bunod, sustaining receptor engagement across a Mean elimination half-life of 7 to 17 hours across adult Latanoprostene Bunod dosing half-life window (oral tmax achieved within 2 to 5 hours following latanoprostene bunod ingestion response profile).
Dosing protocols (.24 mg/mL Solution/ Drops or 0.024%) balance efficacy (78.00% patient satisfaction across 20 logs) against nausea (7.6% of reports), headache (6.6% of reports), dizziness (5.9% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to latanoprostene bunod; clinical scenarios where fda prescription therapeutic agent exposure from latanoprostene bunod poses unacceptable risk.
Verify medication reconciliation lists so Latanoprostene Bunod is not inadvertently duplicated with another fda prescription therapeutic agent.
Botanical enzyme modulators may alter oral first-pass exposure of Latanoprostene Bunod; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Latanoprostene Bunod
- Clinical scenarios where fda prescription therapeutic agent exposure from Latanoprostene Bunod poses unacceptable risk
Logged Side-Effect Incidence (20 Reports)
Latanoprostene Bunod Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Latanoprostene Bunod)
Human clinical trial evidence for Latanoprostene Bunod is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Latanoprostene Bunod Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $99.2842/unit (~$2978.53/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Latanoprostene Bunod Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Latanoprostene Bunod RxNorm Concept ID | 1988394 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $99.2842 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Latanoprostene Bunod Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Latanoprostene Bunod integrating DailyMed SPL (2024-02-27), CMS NADAC ($99.2842/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Latanoprostene Bunod community threads and patient logs by age, biological sex, dosage, and treatment duration.